Clearmind Medicine Inc. (CMND)

USD 0.99

(-3.88%)

Market Cap (In USD)

4.33 Million

Revenue (In USD)

-

Net Income (In USD)

-11.95 Million

Avg. Volume

74.59 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.921-3.58
PE
-0.96
EPS
-1.03
Beta Value
-1.515
ISIN
CA1850534027
CUSIP
-
CIK
1892500
Shares
4383234.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Adi Zuloff-Shani Ph.D.
Employee Count
-
Website
https://www.clearmindmedicine.com
Ipo Date
2022-11-15
Details
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.